WCN25-1572 DESIGN AND BASELINE CHARACTERISTICS OF THE GLOBAL KIDNEY PATIENT TRIALS NETWORK

WCN25-1572 DESIGN AND BASELINE CHARACTERISTICS OF THE GLOBAL KIDNEY PATIENT TRIALS NETWORK

Saved in:

Bibliographic Details
Main Authors:	Sradha Kotwal, Vlado Perkovic, Meg Jardine, Priya Vart, David Wheeler, Ian de Boer, Hong Zhang, Fan Fan Hou, Yuka Sugawara, Luca De Nicola, Jose Gorriz, Hiddo Heerspink
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924025579
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

WCN25-1567 Glomerular disease registry and Biobank (GRIT)– design and baseline results
by: Sradha Kotwal, et al.
Published: (2025-02-01)

Effects of Semaglutide on CKD in Patients With Type 2 Diabetes
by: Sradha S. Kotwal, et al.
Published: (2025-02-01)

Barriers to Care: New Medications and CKD
by: Dana Kim, et al.
Published: (2024-03-01)

WCN24-1868 ASSIST: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER TRIAL OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN) ON SGLT2I
by: Irene L. Noronha, et al.
Published: (2024-04-01)

WCN24-2099 BASELINE CHARACTERISTICS OF THE ALIGN TRIAL: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF ATRASENTAN IN PATIENTS WITH IGAN
by: Hiddo J.L. Heerspink, et al.
Published: (2024-04-01)

WCN24-1980 Efficacy and safety of zibotentan in combination with dapagliflozin in patients with CKD according to baseline diabetes status and kidney function
by: Hiddo Lambers Heerspink, et al.
Published: (2024-04-01)

Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy
by: Hiddo J.L. Heerspink, et al.
Published: (2025-01-01)

Corrigendum to “Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy” [Volume 10, Issue 1, January 2025, Pages 217-226]
by: Hiddo J.L. Heerspink, et al.
Published: (2025-04-01)

System władzy w Polsce ostatnich Jagiellonów (1506-1572)
by: Wacław Uruszczak
Published: (1986-12-01)

WCN24-1572 Deceased Organ Donation: Knowledge, Awareness and Attitude among Family Members of Chronic Kidney Disease Patients in Bangladesh
by: Farnaz Nobi, et al.
Published: (2024-04-01)

Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study
by: Howard Trachtman, et al.
Published: (2024-04-01)

Projects of the Franco-Swedish Alliance against the Russian State in 1572–1575
by: S. M. Ryabov
Published: (2024-12-01)

Z. Trawicka, Sejmik województwa sandomierskiego w latach 1572 - 1696
by: Henryk Olszewski
Published: (1986-05-01)

Inequities in the global representation of sites participating in large, multicentre dialysis trials: a systematic review
by: Brendan Smyth, et al.
Published: (2019-12-01)

Corticosteroid Effects in IgA Nephropathy by Baseline Proteinuria and Estimated GFR
by: Dana Kim, et al.
Published: (2025-06-01)

WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-1537 ASSESSING THE EPIDEMIOLOGY OF CHRONIC KIDNEY DISEASE IN ETHIOPIA USING A POPULATION-BASED NATIONAL ADMINISTRATIVE DATA SOURCE
by: Daniel Ketema, et al.
Published: (2025-02-01)

Mapping the towns of Europe: The European towns in Braun & Hogenberg’s Town Atlas, 1572-1617
by: Peter van der Krogt
Published: (2008-12-01)

Słownictwo politycznych tożsamości w aktach sejmików koronnych z lat 1572–1691
by: Szymon Rutkowski
Published: (2024-10-01)

Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis.
by: Song Ren, et al.
Published: (2017-01-01)

WCN25-499 PATIENT BASELINE CHARACTERISTICS IN THE ONGOING PHASE 3 VISIONARY TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SIBEPRENLIMAB FOR IMMUNOGLOBULIN A NEPHROPATHY
by: Richard Lafayette, et al.
Published: (2025-02-01)

Le parcours de Denis Lambin (1519-1572), précurseur de la « Slow Science » ?
by: Astrid Quillien
Published: (2020-11-01)

WCN24-2313 LONG-TERM SAFETY OF HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS IN CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS
by: Jeffrey Ha, et al.
Published: (2024-04-01)

WCN25-2620 CUMULATIVE EFFECTS OF THE ALDOSTERONE SYNTHASE INHIBITOR VICADROSTAT COMBINED WITH EMPAGLIFLOZIN ON ALBUMINURIA IN PEOPLE WITH CKD
by: Peter Rossing, et al.
Published: (2025-02-01)

WCN24-1766 EFFECTS OF DAPAGLIFLOZIN IN PATIENTS WITH MEMBRANOUS NEPHROPATHY
by: Hiddo J.L. Heerspink, et al.
Published: (2024-04-01)

Localization of the 1572 Battle of Molodi: An Archaeological Aspect (Based on the Results of Works in 2009, 2014, 2017–2018)
by: O. A. Brusentsov
Published: (2022-01-01)

WCN24-606 PROTEOMIC ANALYSIS UNCOVERS NEW CIRCULATING PROTEINS ASSOCIATED WITH INCIDENT HYPERTENSION OVER 15 YEARS IN YOUTH WITH TYPE 2 DIABETES
by: Phoom Narongkiatikhun, et al.
Published: (2024-04-01)

Effects of the Mediterranean Diet on Cardiovascular Outcomes-A Systematic Review and Meta-Analysis.
by: Thaminda Liyanage, et al.
Published: (2016-01-01)

WCN25-1898 IMPLICATIONS OF PROTEINURIA REMISSION ON ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) TRAJECTORY IN PATIENTS (Pts) WITH IgA NEPHROPATHY (IgAN) IN PROTECT
by: Bruce Hendry, et al.
Published: (2025-02-01)

WCN24-1550 ALDOSTERONE SYNTHASE INHIBITION WITH OR WITHOUT BACKGROUND SODIUM GLUCOSE COTRANSPORTER 2 INHIBITION IN CKD: A PHASE II CLINICAL TRIAL
by: Katherine Tuttle, et al.
Published: (2024-04-01)

O mecenas do exemplar de Os Lusíadas de 1572 do Real Gabinete Português de Leitura
by: Gilda Santos
Published: (2025-06-01)

Kinetics of endothelin-1 and effect selective ETA antagonism on ETB activation: a mathematical modeling analysis
by: K. Melissa Hallow, et al.
Published: (2024-11-01)

WCN24-1932 THE ASSOCIATION OF RENAL FUNCTION DETERIORATION WITH BASELINE URICOSURIA
by: Victor Frajewicki, et al.
Published: (2024-04-01)

WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

The relationship between proteinuria and coronary risk: a systematic review and meta-analysis.
by: Vlado Perkovic, et al.
Published: (2008-10-01)

WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-4459 Baseline parameters of patients with FSGS and MN enrolled in the ITANGIBLE registry
by: Kavita Yadav, et al.
Published: (2025-02-01)

Maciej Mikuła, Prawodawstwo króla i sejmu dla małopolskich miast królewskich (1386-1572), Wydawnictwo Uniwersytetu Jagiellońskiego, Kraków 2014, ss. 382.
by: Przemysław Krzywoszyński
Published: (2018-10-01)

WCN24-1132 ACTION3 – Phase 3 study of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS)
by: Jonathon Barratt, et al.
Published: (2024-04-01)